Brivaracetam single and multiple rising oral dose study in healthy Japanese participants: influence of CYP2C19 genotype.
Brivaracetam is a high-affinity synaptic vesicle protein 2A ligand, in phase 3 clinical development for epilepsy. A phase 1, single-center, randomized, double-blind, placebo-controlled, single (2.5-100 mg) and multiple (2.5-50 mg twice daily) rising oral dose study (N01209) was conducted to assess the adverse event profile and pharmacokinetics of brivaracetam in healthy Japanese men, and the influence of the cytochrome P450 (CYP) 2C19 genotype. Plasma and urine were collected serially for analysis of brivaracetam and its three main metabolites: acid, hydroxy and hydroxy acid. Overall, 79/80 randomized participants completed the study. Brivaracetam was generally well tolerated. After single- and multiple-dose administration, brivaracetam was rapidly absorbed, with dose-proportional pharmacokinetics over the dose ranges tested. Steady state was reached after 2 days of repeated dosing. Brivaracetam clearance (averaged across the five single dose levels) was reduced from 0.99 mL/min/kg in homozygous extensive metabolizers (EM; n = 10) to 0.81 mL/min/kg (-18%) in heterozygous EM (n = 17) and 0.70 mL/min/kg (-29%) in poor metabolizers (PM; n = 9). Exposure and urinary excretion of hydroxy metabolite were reduced 10-fold in PM participants, compared with EM participants. Results suggest that brivaracetam is hydroxylated by CYP2C19, but this pathway is minor compared with hydrolysis to the acid metabolite.
UCB Pharma.
Armel
A
Stockis
Shikiko
S
Watanabe
Elisabeth
E
Rouits
Kyoko
K
Matsuguma
Shin
S
Irie
D000284:Administration, Oral; D000328:Adult; D044466:Asian People / Q000235:genetics; D065731:Cytochrome P-450 CYP2C19 / Q000235:genetics* / Q000378:metabolism; D004311:Double-Blind Method; D005838:Genotype; D064368:Healthy Volunteers; D006801:Humans; D007564:Japan; D008297:Male; D011760:Pyrrolidinones / Q000008:administration & dosage* / Q000378:metabolism / Q000493:pharmacokinetics*; D055815:Young Adult
D011760:Pyrrolidinones; D065731:Cytochrome P-450 CYP2C19; C482793:brivaracetam